Immatics Prices $150 Million Stock Sale at $8.69 a Share, With Closing Expected Aug. 26

by Maya Okafor · August 26, 2026

Deals & Listings Reporter, The SmallCap Signal

Immatics N.V., the clinical-stage cancer immunotherapy developer that trades on Nasdaq under the ticker IMTX, has agreed to sell $150 million of equity in an underwritten offering, according to the company announcement published Aug. 25 by StockTitan. The company said it expected the sale to close on Aug. 26, subject to customary closing conditions.

The terms, as set out in that announcement, pair a conventional share sale with a warrant structure that is common in biotech placements. Immatics agreed to sell 12,945,916 ordinary shares at $8.69 each, alongside pre-funded warrants covering a further 4,315,304 ordinary shares priced at $8.689 apiece, with an exercise price of $0.001 per share. The stated $150 million figure is gross proceeds, before underwriting discounts and offering expenses.

Pre-funded warrants are typically used when an investor wants economic exposure to a company without immediately crossing an ownership threshold that would trigger reporting or regulatory limits. The buyer pays almost the entire share price up front and holds a warrant that can be exercised later for a token amount. Immatics did not identify the purchasers in the announcement.

Underwriters were granted a 30-day option to buy up to 2,589,184 additional ordinary shares, the announcement said. Jefferies, Leerink Partners and Cantor acted as joint book-running managers.

The announcement did not specify how the company intends to deploy the money, and it did not restate a cash runway. Both are notable omissions in a financing of this size, and they mean any read on the purpose of the raise has to be drawn from the company's most recent quarterly disclosure rather than from the offering documents summarized in the release.

That quarterly report landed a week earlier. In its second-quarter 2026 results, published Aug. 18, Immatics said it held $448.2 million in cash, cash equivalents and other financial assets as of June 30, 2026, and projected a cash reach into 2028. Those are company-reported figures.

The same release put second-quarter collaboration revenue at $10.4 million, against $5.4 million in the year-earlier quarter. Net loss narrowed to $71.2 million from $80.1 million. Research and development expense moved the other way, rising to $71.1 million from $51.4 million, a reflection of a pipeline that has been pushed into later and more expensive stages of testing.

The most capital-intensive of those is SUPRAME, the Phase 3 trial of anzu-cel, the company's engineered T-cell product also referred to as IMA203. Immatics said in the August results release that it had modified the trial protocol to a single final analysis of progression-free survival with expanded statistical power for overall survival, a change that adds roughly 90 patients and brings the planned enrollment to about 450. Randomizations are expected to be completed by the end of 2026, with topline data anticipated in the first half of 2027 and a biologics license application targeted for 2027.

Expanding a registrational trial by roughly 90 patients is the kind of decision that carries a direct cash cost, and it arrived shortly before the company came to market for equity. Immatics did not link the two in the offering announcement.

On the clinical side, the company reported updated Phase 1b results for anzu-cel showing a 56% confirmed objective response rate in metastatic melanoma, with median overall survival of 16.2 months and a two-year overall survival rate of 46%. Those figures are from the company's own release and have not been independently verified by this publication. Immatics also reported a 63% objective response rate and a 50% confirmed objective response rate for IMA203CD8 in gynecologic cancers.

Elsewhere in the pipeline, the company said its IMA402 bispecific program is in Phase 1b expansion, with combination work alongside IMA401 beginning in squamous non-small cell lung cancer and data anticipated in 2027. It also said the first patient had been dosed in a trial of mRNA-4200 under its Moderna collaboration, an event that triggered a milestone payment to Immatics. The release did not disclose the size of that payment.

Investors in a company at this stage face straightforward mechanics: the share count rises when new equity is issued, and existing holders own a smaller proportion of the same pipeline. Immatics did not publish a post-offering share count in the announcement, so the precise dilution cannot be calculated from the material released. The transaction also remained unclosed as of publication, and the announcement conditioned completion on customary closing conditions.

The financing lands in a market that has been receptive to risk. The Nasdaq Composite closed Tuesday, Aug. 25, at 26,151.30, up 171.11 points or 0.66%, in the last completed session before the offering was due to settle. U.S. markets were open at the time of writing and no closing level for Wednesday's session was available.